Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I W Flinn

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 6, 2017
Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomasR Karmali, E Kimby, M Ghielmini, et al.
Leukemia Research|May 5, 2001
Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemiaJ K Waselenko, M R Grever, C A Shinn, et al.
Leukemia & Lymphoma|November 8, 2001
Carboxyamido-triazole (CAI)--a novel "static" signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cellsJ K Waselenko, C A Shinn, C R Willis, et al.
Experimental Hematology|May 30, 2001
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanismJ C Byrd, C Shinn, C R Willis, et al.
Alcoholism, Clinical and Experimental Research|December 1, 1991
Effects of chronic ethanol exposure on cardiac receptor-adenylyl cyclase coupling: studies in cultured embryonic chick myocytes and ethanol fed ratsR S Blumenthal, I W Flinn, O Proske, et al.
Blood|August 10, 1999
Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cellsJ C Byrd, C Shinn, R Ravi, et al.
Blood|December 9, 2000
Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical responseJ Yang, Q Tao, I W Flinn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 29, 2000
Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphomaI W Flinn, P V O'Donnell, A Goodrich, et al.
Seminars in Oncology|July 6, 2000
Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disordersJ C Byrd, M R Grever, J K Waselenko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2000
A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHLI W Flinn, S N Goodman, L Post, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 6, 2017
Rituximab: a benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomasR Karmali, E Kimby, M Ghielmini, et al.
Leukemia Research|May 5, 2001
Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemiaJ K Waselenko, M R Grever, C A Shinn, et al.
Leukemia & Lymphoma|November 8, 2001
Carboxyamido-triazole (CAI)--a novel "static" signal transduction inhibitor induces apoptosis in human B-cell chronic lymphocytic leukemia cellsJ K Waselenko, C A Shinn, C R Willis, et al.
Experimental Hematology|May 30, 2001
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanismJ C Byrd, C Shinn, C R Willis, et al.
Alcoholism, Clinical and Experimental Research|December 1, 1991
Effects of chronic ethanol exposure on cardiac receptor-adenylyl cyclase coupling: studies in cultured embryonic chick myocytes and ethanol fed ratsR S Blumenthal, I W Flinn, O Proske, et al.
Blood|August 10, 1999
Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cellsJ C Byrd, C Shinn, R Ravi, et al.
Blood|December 9, 2000
Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical responseJ Yang, Q Tao, I W Flinn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 29, 2000
Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphomaI W Flinn, P V O'Donnell, A Goodrich, et al.
Seminars in Oncology|July 6, 2000
Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disordersJ C Byrd, M R Grever, J K Waselenko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2000
A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHLI W Flinn, S N Goodman, L Post, et al.
Pageof 4